This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Compugen Discloses Predictive Structural Biology Infrastructure Platform For Enhanced Discovery Of Novel Drugs

Compugen Ltd. ( NASDAQ: CGEN) announced today the ongoing development of a Predictive Structural Biology (PSB) Infrastructure Platform designed to computationally identify the functional interaction sites of proteins, which are of substantial importance for the rational design of novel drugs. The current application of this new infrastructure capability aims at enhanced discovery of functional monoclonal antibodies in cancer and immunology, Compugen’s core areas of focus.

Protein interactions are central to key biological functions, and thus the therapeutic applications of modulating such interactions are wide-ranging and of high industry interest. In general, modulation occurs when the drug binds to the protein's functional interaction sites. However, the correct identification of functional interaction sites of proteins has in many cases proven to be challenging. Accurately predicting functional interaction sites would therefore be of great help in the design of novel drugs.

In the area of therapeutic antibodies, which represents one of the fastest growing segments in pharmaceuticals, there have been important advances in multiple technologies developed for accelerating therapeutic antibody discovery. However, generating antibodies having the required biological and therapeutic functions remains very difficult. The current application of the PSB Infrastructure Platform targets this problem.

The development of this new infrastructure platform relies heavily on the integration of capabilities previously developed for Compugen’s PPI Blockers Discovery Platform, such as computational prediction of protein-protein interaction sites, certain protein engineering know-how, and, specifically for the therapeutic antibody application, a molecular analysis of antibody-antigen interactions.

Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “The flexibility of the PSB Infrastructure Platform creates the potential to provide a wide range of drug discovery capabilities and applications, and therefore it is expected to be an important addition to Compugen’s unique predictive infrastructure.”

Dr. Cohen-Dayag continued, “The current application of this new capability is being designed not only to enhance the discovery of functional therapeutic monoclonal antibodies that modulate Compugen-discovered novel targets, but also to allow us to generate monoclonal antibodies against additional targets, such as those that have to date proven refractory to antibody targeting attempts. The uniqueness of the current application is its focus on functional protein regions, thereby increasing the likelihood of generating functional antibodies with the desired therapeutic activity. Furthermore, future modifications of the current application may enable us to introduce selected specificities to a given antibody in a predictable manner.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs